Loading clinical trials...

RECRUITINGNA

Inspiratory Muscle Training in HFpEF

Inspiratory Muscle Training in Heart Failure With Preserved Ejection Fraction

NCT06510231•Mayo Clinic

Summary

This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•≥18 yrs of age
•Receiving SGLT2 inhibitors and spironolactone (and beta-blocker use for HFpEF patients with hypertension) for \>3 months
•NYHA symptoms I-III
•Body mass index ≤40 kg/m2
•Currently non-smokers with \<20 pack year history
•Able to exercise (i.e. without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise)

Exclusion Criteria

•Sustained ventricular tachycardia and/or ventricular fibrillation within 21 days of visit 1
•Second or third degree heart block
•Body mass index \>40 kg/m2
•Current smokers and/or smoking history \>20 pack years
•Pregnant women (testing will be done by research team if requested)
•Glomerular filtration rate of \<30 mL/min/1.73m2 (initial screen via clinical record within the past 6 months and this will be assessed on Visit 1)
•Individuals who are not able to engage in exercise
•Uremia, history of allergy to iodides
•Peripheral artery disease
•Alanine transaminase and/or aspartate transaminase greater than 2 times the upper limit of normal (via clinical record within the past 6 months)
+4 more criteria

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

October 9, 2024

Primary Completion Date

April 1, 2028

Completion Date

April 1, 2028

Last Updated

October 20, 2025

Enrollment

ESTIMATED participants

Conditions

Heart Failure

Interventions

Inspiratory Muscle Training

OTHER

Contacts

Eric Bruhn, M.A.

CONTACT

507-266-2690 bruhn.eric@mayo.edu

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITING

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Inspiratory Muscle Training in HFpEF

Inclusion Criteria

Exclusion Criteria

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation